Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase NA 14Phase 1 13Phase 1/2 7Phase 3 5Phase EARLY_PHASE1 3Phase 4 3Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 7Thyroid Carcinoma, Anaplastic 3Thyroid Cancer, Papillary 3Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Thyroid Neoplasms 2Somatostatinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Laryngeal Neoplasms 2Hematologic Neoplasms 2Glioma 2Gastroenteropancreatic Neuroendocrine Tumors 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2Vipoma 1Thyroid cancer, Hurthle cell 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Muscle Weakness 1Motor Activity 1Melanoma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Pheochromocytoma × Endocrine × Clear all
NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Radio Isotope Therapy of America

Phase 2/3 Completed
200 enrolled
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡